Notably, PLC stem cells are characterized by high CD44 expression, making this receptor a compelling target for therapeutic strategies aimed at achieving tumor regression and reducing recurrence through the eradication of cancer stem cells [141,142,143,144]. The gene discussed is HSPG2; the disease is neoplasm.